Practice of ADRB2, GLCCIl, FCER2 Gene Detection in Individualized Medication of 2 Children with Refractory Asthma
10.6039/j.issn.1001-0408.2018.05.21
- VernacularTitle:ADRB2、GLCCI1、FCER2基因检测在2例难治性哮喘患儿个体化用药中的实践
- Author:
Danyang REN
1
;
Yunwei LI
;
Caixia TU
;
Jianling SHEN
;
Jing ZONG
;
Aihua YAN
;
Tao XU
;
Huiying LI
Author Information
1. 昆明医科大学附属儿童医院药剂科
- Keywords:
Refractory asthma;
Gene test;
Clinical pharmacists;
Individualized drug therapy
- From:
China Pharmacy
2018;29(5):659-662
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To study the value of ADRB2, GLCCI1, FCER2 gene detection in individualized medication of children with refractory asthma.METHODS: Clinical pharmacists participated in therapy for 2 cases of refractory asthma, and comprehensively analyzed risk factors as its pathogenic factors (allergens and pathogens of respiratory infections), lung function indexes and family history. It was suggested to conduct anti-asthmatic drugs gene [p2-adrenergic receptor (ADRB2), glucocorticoid induced transcriptional 1 gene (GLCCI1), low affinity IgE receptor (FCER2)] testing. According to detection results, the suggestions were put forward such as increasing the dose of Glucocorticoid for inhalation, stopping β2 receptor agonist, additionally using anticholinergic drug. RESULTS: The clinical physicians adopted the suggestions of clinical pharmacists. After optimizing refractory asthma therapy plan according to the results of gene testing and clinical factors, 2 patients were stable and the number of seizures decreased significanthy. CONCLUSIONS: Gene test can provide evidence for the formulation of individualized therapy in asthma children.
